Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Overview
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Companies Involved in Therapeutics Development
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sires LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug Profiles
Antisense Ri Oligonucleotide to Agonize RIG1 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-9400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLR-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate RIG-I for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target RIG-I for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Discontinued Products
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Bioncotech Therapeutics phase I BO-112 data presented at ESMO Immuno-Oncology Congress 2019
Oct 14, 2019: A Yale-developed drug shows promise as immune therapy for cancer
Oct 09, 2018: Merck to present data on tumor drug candidate MK-4621 at ESMO 2018
May 03, 2017: Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Bioncotech Therapeutics SL, H1 2020
Pipeline by Kineta Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Sirenas LLC, H1 2020
Pipeline by Spring Bank Pharmaceuticals Inc, H1 2020
Pipeline by Vycellix Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020